U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H23N.ClH
Molecular Weight 313.864
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMITRIPTYLINE HYDROCHLORIDE

SMILES

Cl.CN(C)CCC=C1C2=C(CCC3=C1C=CC=C3)C=CC=C2

InChI

InChIKey=KFYRPLNVJVHZGT-UHFFFAOYSA-N
InChI=1S/C20H23N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-12H,7,13-15H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C20H23N
Molecular Weight 277.4033
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.rxlist.com/elavil-drug.htm https://www.ncbi.nlm.nih.gov/pubmed/23235671; https://www.ncbi.nlm.nih.gov/pubmed/11157426; http://www.ncbi.nlm.nih.gov/pubmed/16871467; http://www.ncbi.nlm.nih.gov/pubmed/2578912; http://www.ncbi.nlm.nih.gov/pubmed/?term=15943846

Amitriptyline is a derivative of dibenzocycloheptadiene and a tricyclic antidepressant (TCA) and is mainly used to treat symptoms of depression. It works on the central nervous system (CNS) by inhibiting the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Amitriptyline has been frequently used as an active comparator in clinical trials on newer antidepressants. It is rarely used as a first-line antidepressant nowadays due to its high degree of toxicity in overdose and generally poorer tolerability than the newer antidepressants.

CNS Activity

Originator

Approval Year

1961
132
Targets

Targets

Primary TargetPharmacologyConditionPotency
Sodium-dependent noradrenaline transporter
38
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
Inhibitor
8146
 3.45 nM [IC50]
Sodium-dependent serotonin transporter
41
Target ID: P31645
Gene ID: 6532.0
Gene Symbol: SLC6A4
Target Organism: Homo sapiens (Human)
Inhibitor
8146
 13.3 nM [IC50]
5-hydroxytryptamine receptor 2A
69
Target ID: P28223
Gene ID: 3356.0
Gene Symbol: HTR2A
Target Organism: Homo sapiens (Human)
Antagonist
2737
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Approved
8307
AMITRIPTYLINE HYDROCHLORIDE

Approved Use

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states.

Launch Date

8.7393599E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.3 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10383563
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
593 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10383563
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/10383563
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.7%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6125396
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMITRIPTYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Disc. AE: Bradycardia...
Other AEs: Agitation, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Bradycardia (grade 3, 20%)
Other AEs:
Agitation (20%)
Dry mouth (20%)
Drowsiness (20%)
Language disorder (20%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
Other AEs: Thought disorder, Mental concentration difficult...
Other AEs:
Thought disorder
Mental concentration difficult
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
healthy, mean age 22.1 years
n = 96
Health Status: healthy
Age Group: mean age 22.1 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
Other AEs: Mental status changes...
Other AEs:
Mental status changes
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Other AEs: Dry mouth, Sleepiness...
Other AEs:
Dry mouth (75%)
Sleepiness (68.8%)
Dizziness (25%)
Constipation (18.8%)
Palpitations (6.3%)
Malaise (6.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Disc. AE: Drowsiness, Dry mouth...
Other AEs: Drowsiness, Nausea...
AEs leading to
discontinuation/dose reduction:
Drowsiness (10%)
Dry mouth (10%)
Other AEs:
Drowsiness (51.8%)
Nausea (7.4%)
Headache (7.4%)
Dry mouth (63%)
Thirst (7.4%)
Tiredness (7.4%)
Bad taste (18.5%)
Attention concentration difficulty (7.4%)
Hyperglycaemia (3.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Disc. AE: Ankle edema, Dizziness...
Other AEs: Sedation, Dry mouth...
AEs leading to
discontinuation/dose reduction:
Ankle edema (4%)
Dizziness (4%)
Other AEs:
Sedation (32%)
Dry mouth (32%)
Postural hypotension (20%)
Weight gain (24%)
Ataxia (8%)
Constipation (12%)
Lethargy (20%)
Edema (8%)
Headache (12%)
Pruritus (12%)
Bad taste (4%)
Nausea (4%)
Diarrhea (4%)
Blurred vision (8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
healthy
n = 96
Health Status: healthy
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
Other AEs: Tachycardia...
Other AEs:
Tachycardia
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
AEs

AEs

AESignificanceDosePopulation
Agitation 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Drowsiness 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Dry mouth 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Language disorder 20%
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Bradycardia grade 3, 20%
Disc. AE
100 mg 1 times / day single, intravenous
Studied dose
Dose: 100 mg, 1 times / day
Route: intravenous
Route: single
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
healthy, 21 to 70 years
n = 5
Health Status: healthy
Age Group: 21 to 70 years
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/17512256/
Mental concentration difficult
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
Thought disorder
10 % 1 times / day single, topical
Highest studied dose
Dose: 10 %, 1 times / day
Route: topical
Route: single
Dose: 10 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
unhealthy, 57 years
n = 1
Health Status: unhealthy
Condition: pain
Age Group: 57 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/21676162/
Mental status changes
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
healthy, mean age 22.1 years
n = 96
Health Status: healthy
Age Group: mean age 22.1 years
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
Constipation 18.8%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Dizziness 25%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Malaise 6.3%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Palpitations 6.3%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Sleepiness 68.8%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Dry mouth 75%
25 mg 1 times / day multiple, oral
Studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
unhealthy, mean age 43.2 years
n = 16
Health Status: unhealthy
Condition: globus pharyngeus
Age Group: mean age 43.2 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/24259978/
Drowsiness 10%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Dry mouth 10%
Disc. AE
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Bad taste 18.5%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Hyperglycaemia 3.7%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Drowsiness 51.8%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Dry mouth 63%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Attention concentration difficulty 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Headache 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Nausea 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Thirst 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Tiredness 7.4%
75 mg 1 times / day multiple, oral
Recommended
Dose: 75 mg, 1 times / day
Route: oral
Route: multiple
Dose: 75 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
unhealthy, mean age 55 years
n = 27
Health Status: unhealthy
Condition: chronic pain
Age Group: mean age 55 years
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/8494126/
Constipation 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Headache 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Pruritus 12%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Lethargy 20%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Postural hypotension 20%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Weight gain 24%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Dry mouth 32%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Sedation 32%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Bad taste 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Diarrhea 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Nausea 4%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Ankle edema 4%
Disc. AE
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Dizziness 4%
Disc. AE
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Ataxia 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Blurred vision 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Edema 8%
59 mg 1 times / day multiple, oral (mean)
Studied dose
Dose: 59 mg, 1 times / day
Route: oral
Route: multiple
Dose: 59 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
unhealthy, mean age 60.4 years
n = 25
Health Status: unhealthy
Condition: diabetic peripheral neuropathy pain
Age Group: mean age 60.4 years
Sex: M+F
Population Size: 25
Sources:
https://pubmed.ncbi.nlm.nih.gov/10493324/
Tachycardia
520.3 mg 1 times / day single, oral (mean)
Studied dose
Dose: 520.3 mg, 1 times / day
Route: oral
Route: single
Dose: 520.3 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
healthy
n = 96
Health Status: healthy
Sex: M+F
Population Size: 96
Sources:
https://pubmed.ncbi.nlm.nih.gov/20923818/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532
substrate
985
substrate
1168

inhibitor
1789
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
1410

CYP2C8
869

OCT1
498

OCT2
630
CYP1A2
1013

CYP2C19
955

CYP2B6
648

UGT2B10
127

UGT1A4
345
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OCT2
631
 yes [IC50 14 uM]
OCT1
513
 yes [IC50 6.99 uM]
CYP3A4
1857
 yes [IC50 8.8 uM]
CYP2C8
923
 yes [Inhibition 200 uM]
CYP2D6
1826
 yes [Ki 31 uM]
CYP2C19
1484
 yes [Ki 37.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1013
 no
CYP2C19
955
 no
CYP2B6
648
 yes
CYP2C9
985
 yes
CYP2D6
1168
 yes
CYP3A4
1670
 yes
UGT1A4
345
 yes
UGT2B10
127
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:2666
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2666
MolPort
MolPort-001-662-651
https://www.molport.com/shop/molecule-link/MolPort-001-662-651
ZINC
ZINC000000968257
http://zinc15.docking.org/substances/ZINC000000968257
eMolecules
739635
https://www.emolecules.com/cgi-bin/more?vid=739635
PubMed

PubMed

TitleDatePubMed
Seizures during lithium-amitriptyline therapy.
1979 Sep
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
1999 Aug
Syncope associated with concurrent amitriptyline and fluconazole therapy.
2000 Dec
Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds.
2000 Jul 28
Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline.
2000 Mar
[Extrapyramidal reactions after epidural droperidol].
2000 Oct
Near fatal case of atrio-ventricular block induced by amitriptyline at therapeutic dose.
2000 Sep
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.
2000 Sep
Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers.
2000 Sep
Long-term effects of tricyclic antidepressants on norepinephrine kinetics in humans.
2001
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.
2001
Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants.
2001
Noradrenergic dysfunction and antidepressant treatment response.
2001 Apr
Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability.
2001 Apr
Combined pharmacotherapy for nocturnal enuresis.
2001 Aug
Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine.
2001 Aug
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
2001 Aug
Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta.
2001 Feb
Gabapentin for the treatment of tinnitus: a case report.
2001 Feb
Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: results of a placebo controlled study.
2001 Feb
Salmon calcitonin potentiates the analgesia induced by antidepressants.
2001 Jan
Weight outcomes among antidepressant users in nursing facilities.
2001 Jan
Lamotrigine for central poststroke pain: a randomized controlled trial.
2001 Jan 23
Isolated sural neuropathy presenting as lateral ankle pain.
2001 Jul
Antinociception by tricyclic antidepressants in the rat formalin test: differential effects on different behaviours following systemic and spinal administration.
2001 Jul
[Ciguatera: clinical relevance of a marine neurotoxin].
2001 Jul 13
Efficacy of amitriptyline as a pharmacological adjunct to behavioral modification in the management of aggressive behaviors in dogs.
2001 Jul-Aug
Acute eosinophilic pneumonia associated with amitriptyline in a hemodialysis patient.
2001 Jun
Pharmacological modulation of SK3 channels.
2001 Jun
Effects of amitriptyline on diurnal variations of oxidation-reduction enzyme activities in rat lymphocytes during experimental desynchronosis.
2001 May
Treatment of neuropathic pain with venlafaxine.
2001 May
Advances in the management of neuropathic pain.
2001 May
Combining psychotherapy and antidepressants in the treatment of depression.
2001 May
Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial.
2001 May 2
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
2001 Oct
Efficacy of spinal manipulation for chronic headache: a systematic review.
2001 Sep
Drug use and five-year incidence of age-related cataracts: The Beaver Dam Eye Study.
2001 Sep
Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care.
2001 Sep 22
Patents

Patents

JP2007512339A
42
JP2007525670A
147
JP2011528275A
445
JP4653399B2
50
JPS5569567A
7

Sample Use Guides

In Vivo Use Guide
For outpatients, 75 mg of amitriptyline HCl a day in divided doses. If necessary, this may be increased to a total of 150 mg per day. An alternate method of initiating therapy in outpatients is to begin with 50 to 100 mg amitriptyline HCl at bedtime. This may be increased by 25 or 50 mg as necessary in the bedtime dose to a total of 150 mg per day. Hospitalized patients may require 100 mg a day initially. This can be increased gradually to 200 mg a day if necessary up to 300 mg a day. Not recommended for patients under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Amitriptyline was used at 40 uM in isolated rat hepatocytes for 60,120,180 min.
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:44:39 UTC 2022
Edited
by admin
on Fri Dec 16 17:44:39 UTC 2022
Record UNII
26LUD4JO9K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMITRIPTYLINE HYDROCHLORIDE
EP   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [MI]
Common Name English
LIMBITROL DS COMPONENT AMITRIPTYLINE HYDROCHLORIDE
Common Name English
AMITRIPTYLINE HYDROCHLORIDE COMPONENT OF LIMBITROL DS
Common Name English
LIMBITROL COMPONENT AMITRIPTYLINE HYDROCHLORIDE
Common Name English
NSC-104210
Code English
AMITRIPTYLINE HYDROCHLORIDE [MART.]
Common Name English
AMITRIPTYLINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
SYNEUDON
Common Name English
Amitriptyline hydrochloride [WHO-DD]
Common Name English
ENDEP
Brand Name English
AMITID
Brand Name English
AMITRIPTYLINE HYDROCHLORIDE COMPONENT OF LIMBITROL
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [WHO-IP]
Common Name English
NOVOPROTECT
Common Name English
ELAVIL
Brand Name English
ETRAVIL
Brand Name English
AMITRIPTYLINE HYDROCHLORIDE [USP IMPURITY]
Common Name English
AMITRIL
Brand Name English
AMITRIPTYLINE HYDROCHLORIDE [EP IMPURITY]
Common Name English
ETRAFON-A COMPONENT AMITRIPTYLINE HYDROCHLORIDE
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [VANDF]
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
AMITRIPTYLINE HYDROCHLORIDE COMPONENT OF ETRAFON-A
Common Name English
NIH 10794
Code English
AMITRIPTYLINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
AMITRIPTYLINE HCL
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [JAN]
Common Name English
AMITRIPTYLINE HYDROCHLORIDE [USP-RS]
Common Name English
1-PROPANAMINE, 3-(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-, HYDROCHLORIDE
Systematic Name English
AMITRIPTYLINE HYDROCHLORIDE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C94727
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
Code System Code Type Description
RS_ITEM_NUM
1029002
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
CAS
549-18-8
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
DAILYMED
26LUD4JO9K
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
AMITRIPTYLINE HYDROCHLORIDE
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY Description: Colourless crystals or a white or almost white powder; odourless or almost odourless. Solubility: Soluble in 1 part of water and in 1.5 parts of ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antidepressant. Storage: Amitriptyline hydrochloride should be kept in a tightly closed container, protected from light. Additional information: Amitriptyline hydrochloride has a bitter and burning taste that is followed by a sensation of numbness. Even in the absence of light, Amitriptyline hydrochloride is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Amitriptyline hydrochloride contains not less than 99.0% and not more than 101.5% of C20H23N,HCl, calculated with reference to the dried substance.
ECHA (EC/EINECS)
208-964-6
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
PUBCHEM
11065
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
FDA UNII
26LUD4JO9K
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
DRUG BANK
DBSALT000009
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
MERCK INDEX
M1753
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY Merck Index
NSC
104210
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
ChEMBL
CHEMBL629
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
EVMPD
SUB00474MIG
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
NCI_THESAURUS
C28819
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
RXCUI
203168
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY RxNorm
EPA CompTox
DTXSID9033187
Created by admin on Fri Dec 16 17:44:39 UTC 2022 , Edited by admin on Fri Dec 16 17:44:39 UTC 2022
PRIMARY
Related Record Type Details
Structure of AMITRIPTYLINE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of AMITRIPTYLINE
PARENT -> SALT/SOLVATE
Structure of AMITRIPTYLINE HYDROCHLORIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of NORTRIPTYLINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DIBENZOSUBEROL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYCLOBENZAPRINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORTRIPTYLINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIBENZOSUBERONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of AMITRIPTYNOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DIBENZOSUBERONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of AMITRIPTYNOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYCLOBENZAPRINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of AMITRIPTYLINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966